Claims for Patent: 9,677,061

Summary for Patent: 9,677,061

Title:	Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
Abstract:	Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
Inventor(s):	Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	12/928,890
Patent Claims:	1. A viral vector, comprising a sequence of nucleotides that encodes a C-terminal truncated hyaluronidase polypeptide and an adjacent stop codon positioned so that the truncated polypeptide is produced upon expression of the sequence of nucleotides, wherein: the truncated hyaluronidase polypeptide is a soluble neutral active hyaluronidase polypeptide; the truncated hyaluronidase polypeptide does not comprise the full-length of the polypeptide whose sequence is set forth in SEQ ID NO: 1; and the truncated hyaluronidase polypeptide is selected from among: i) a hyaluronidase polypeptide that consists of a contiguous sequence of amino acids contained within SEQ ID NO:1, contains residues 36-464 of SEQ ID NO: 1, and terminates at an amino acid residue that is selected from 477, 478, 479, 480, 481, 482 or 483 of SEQ ID NO:1; or ii) a hyaluronidase polypeptide comprising amino acid substitutions in the sequence of i), whereby the hyaluronidase polypeptide comprising amino acid substitutions has at least 95% sequence identity with the polypeptide of i) and terminates at a residue corresponding to any of residues 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1. 2. The vector of claim 1, wherein the vector is an adenovirus vector. 3. The vector of claim 1, wherein the vector is a retrovirus vector. 4. The vector of claim 1, wherein the vector is a vaccinia virus vector. 5. The vector of claim 1, comprising a sequence of nucleotides set forth in SEQ ID NO:48, which encodes amino acids 1-482 of SEQ ID NO:1. 6. The vector of claim 1, wherein the vector comprises nucleotides 106-1446 of SEQ ID NO: 6, which encodes amino acid resides 36-482 of SEQ ID NO:1. 7. The vector of claim 1, wherein the vector encodes a signal sequence for secretion of the encoded polypeptide. 8. The vector of claim 7, wherein the signal sequence is an IgG kappa chain leader peptide. 9. The vector of claim 8, wherein the IgG kappa chain leader peptide has a sequence of nucleotides set forth in SEQ ID NO:43. 10. An isolated cell, comprising the vector of claim 1. 11. The isolated cell of claim 10, wherein the encoded polypeptide is secreted from the cell. 12. The isolated cell of claim 10, wherein the cell is a eukaryotic cell. 13. The isolated cell of claim 12, wherein the cell is a mammalian cell. 14. The isolated cell of claim 12, wherein the cell is a Chinese hamster ovary (CHO) cell. 15. The viral vector of claim 1, wherein the nucleic acid encoding the truncated hyaluronidase polypeptide is cDNA. 16. A cell culture, comprising the vector of claim 1. 17. An adenovirus vector, comprising a sequence of nucleotides encoding a hyaluronidase polypeptide, wherein: the encoded hyaluronidase polypeptide has at least 98% sequence identity to the sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO:1; and the adenovirus vector comprises a sequence of nucleotides that encodes a stop codon positioned adjacent to the encoding sequence so that the hyaluronidase polypeptide is produced upon expression. 18. The adenovirus vector of claim 17, wherein the sequence of amino acids of the encoded polypeptide comprises a contiguous sequence of amino acid residues that includes residues 36-464 of SEQ ID NO:1 and terminates at a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1. 19. The vector of claim 17, comprising a sequence of nucleotides set forth in SEQ ID NO:48, which encodes amino acids 1-482 of SEQ ID NO:1. 20. The vector of claim 17, wherein the vector comprises nucleotides 106-1446 of SEQ ID NO:6, which encodes amino acids 36-482 of SEQ ID NO:1. 21. The vector of claim 17, wherein the vector encodes a signal sequence for secretion of the encoded polypeptide. 22. The vector of claim 21, wherein the signal sequence is an IgG kappa chain leader peptide. 23. The vector of claim 22, wherein the IgG kappa chain leader peptide has a sequence of nucleotides set forth in SEQ ID NO:43. 24. An isolated cell, comprising the vector of claim 17. 25. The isolated cell of claim 24, wherein the encoded polypeptide is secreted from the cell. 26. The isolated cell of claim 25, wherein the cell is a eukaryotic cell. 27. The isolated cell of claim 26, wherein the cell is a mammalian cell. 28. The isolated cell of claim 26, wherein the cell is a Chinese hamster ovary (CHO) cell. 29. A cell culture, comprising the vector of claim 17. 30. The adenovirus vector of claim 17, wherein the nucleic acid encoding the truncated hyaluronidase polypeptide is cDNA.

Details for Patent 9,677,061

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2023-03-05
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2023-03-05
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2023-03-05
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2023-03-05